← Back to Search

Anti-metabolites

Paclitaxel + Folic Acid + Lometrexol for Cancer

Phase 1

Waitlist Available

Research Sponsored by Jonsson Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No inflammatory bowel disease, No radiation enteritis, No malabsorption syndrome

Histologically or cytologically proven locally advanced or metastatic solid tumor that is refractory to standard therapies or for which there are no therapies of potential major benefit

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well giving paclitaxel, folic acid, and lometrexol together works in treating patients with solid tumors.

Who is the study for?

This trial is for adults with advanced or metastatic solid tumors that haven't responded to standard treatments. Participants must have a life expectancy of at least 12 weeks, measurable disease, and no severe illnesses that could interfere with the study. They should not be pregnant or nursing and must use contraception if fertile.Check my eligibility

What is being tested?

The trial tests a combination of paclitaxel (a chemotherapy drug), folic acid (which may protect normal cells and make tumor cells more sensitive to treatment), and lometrexol (an enzyme blocker) in patients with advanced solid tumors to see if this mix can better kill cancer cells.See study design

What are the potential side effects?

Potential side effects include those typical of chemotherapy such as nausea, fatigue, hair loss, increased risk of infection due to low blood cell counts, nerve damage leading to numbness or tingling sensations, and allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I do not have inflammatory bowel disease, radiation enteritis, or malabsorption syndrome.

Select...

My advanced cancer does not respond to standard treatments.

Select...

I am fully active or able to carry out light work.

Select...

I am 18 years old or older.

Select...

My cancer can be measured by tests.

Select...

My liver function tests are within the required range.

Select...

My kidneys filter blood at a rate of at least 65 mL/min.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 7Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,687 Previous Clinical Trials

40,930,371 Total Patients Enrolled

Jonsson Comprehensive Cancer CenterLead Sponsor

361 Previous Clinical Trials

27,782 Total Patients Enrolled

Lee S. Rosen, MDStudy ChairJonsson Comprehensive Cancer Center

5 Previous Clinical Trials

Media Library

Lometrexol (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT00024310 — Phase 1

Drug Toxicity Clinical Trial 2023: Lometrexol Highlights & Side Effects. Trial Name: NCT00024310 — Phase 1

Lometrexol (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00024310 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment still available for this research trial?

"The clinicaltrials.gov page for this research indicates that the study is not currently looking to add any more patients, having been initially posted in September of 2001 with an update made on September 16th 2013. However, there are still 83 other trials actively recruiting participants at present."

Answered by AI

What potential perils exist for individuals undergoing this procedure?

"As this is a Phase 1 trial, our team at Power has rated its safety as a 1 due to the reduced amount of evidence supporting both effectiveness and security."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors

2001. "Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00024310.

All > Acl